Wunder A - Search Results

1

Antitumor activity of methotrexate-albumin conjugates in rats bearing a Walker-256 carcinoma.

Wunder A, Stehle G, Schrenk HH, Hartung G, Heene DL, Maier-Borst W, Sinn H. Wunder A, et al. Int J Cancer. 1998 Jun 10;76(6):884-90. doi: 10.1002/(sici)1097-0215(19980610)76:6<884::aid-ijc19>3.0.co;2-2. Int J Cancer. 1998. PMID: 9626357

2

Methotrexate-induced accumulation of fluorescent annexin V in collagen-induced arthritis.

Wunder A, Schellenberger E, Mahmood U, Bogdanov A Jr, Müller-Ladner U, Weissleder R, Josephson L. Wunder A, et al. Mol Imaging. 2005 Jan-Mar;4(1):1-6. Mol Imaging. 2005. PMID: 15967121

3

Magnetic resonance imaging of the pancreas and pancreatic tumors in a mouse orthotopic model of human cancer.

Grimm J, Potthast A, Wunder A, Moore A. Grimm J, et al. Among authors: wunder a. Int J Cancer. 2003 Sep 20;106(5):806-11. doi: 10.1002/ijc.11281. Int J Cancer. 2003. PMID: 12866043

4

Lack of evidence for inhibition of angiogenesis as a central mechanism of the antiarthritic effect of methotrexate.

Fiehn C, Wunder A, Krienke S, Max R, Ho AD, Moehler T. Fiehn C, et al. Among authors: wunder a. Rheumatol Int. 2005 Mar;25(2):108-13. doi: 10.1007/s00296-003-0408-y. Epub 2003 Nov 15. Rheumatol Int. 2005. PMID: 14618373

5

Efficacy and tolerability of an aminopterin-albumin conjugate in tumor-bearing rats.

Kremer P, Hartung G, Bauder-Wüst U, Schrenk HH, Wunder A, Heckl S, Zillmann U, Sinn H. Kremer P, et al. Among authors: wunder a. Anticancer Drugs. 2002 Jul;13(6):615-23. doi: 10.1097/00001813-200207000-00008. Anticancer Drugs. 2002. PMID: 12172507

6

Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis.

Wunder A, Müller-Ladner U, Stelzer EH, Funk J, Neumann E, Stehle G, Pap T, Sinn H, Gay S, Fiehn C. Wunder A, et al. J Immunol. 2003 May 1;170(9):4793-801. doi: 10.4049/jimmunol.170.9.4793. J Immunol. 2003. PMID: 12707361

7

Albumin-based drug carriers: comparison between serum albumins of different species on pharmacokinetics and tumor uptake of the conjugate.

Stehle G, Wunder A, Schrenk HH, Hartung G, Heene DL, Sinn H. Stehle G, et al. Among authors: wunder a. Anticancer Drugs. 1999 Sep;10(8):785-90. Anticancer Drugs. 1999. PMID: 10573211

8

Methotrexate-albumin conjugate causes tumor growth delay in Dunning R3327 HI prostate cancer-bearing rats.

Stehle G, Wunder A, Schrenk HH, Hartung G, Heene DL, Sinn H. Stehle G, et al. Among authors: wunder a. Anticancer Drugs. 1999 Apr;10(4):405-11. doi: 10.1097/00001813-199904000-00009. Anticancer Drugs. 1999. PMID: 10378676

9

Pharmacokinetics of methotrexate-albumin conjugates in tumor-bearing rats.

Stehle G, Wunder A, Sinn H, Schrenk HH, Schütt S, Frei E, Hartung G, Maier-Borst W, Heene DL. Stehle G, et al. Among authors: wunder a. Anticancer Drugs. 1997 Oct;8(9):835-44. doi: 10.1097/00001813-199710000-00004. Anticancer Drugs. 1997. PMID: 9402310

10

The loading rate determines tumor targeting properties of methotrexate-albumin conjugates in rats.

Stehle G, Sinn H, Wunder A, Schrenk HH, Schütt S, Maier-Borst W, Heene DL. Stehle G, et al. Among authors: wunder a. Anticancer Drugs. 1997 Aug;8(7):677-85. Anticancer Drugs. 1997. PMID: 9311444

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results